Pediatric nephroblastoma has transformed from a mortality rate of 80% or more in the 1920s and 1930s to a current survival rate of 80% or more. Although most have a favorable prognosis, a subset of patients in the high-risk group requiring more effective treatment have a poorer prognosis. Factors associated with prognosis in the context of rational combination therapy are: 1. Pathologic tissue type and staging: for tissue structures with a good prognosis at NWTS-2, the 2-year survival rate is already 90%, for tissue structures with a poor prognosis only 54%. Among the histologic structures with good prognosis, 65% of the cases are in stage I or II; while among the histologic structures with bad prognosis, 50% of the cases are in stage III or IV. 2. Presence or absence of lymph node metastasis: the survival rate of cases with lymph node metastasis is 54%, while the survival rate of cases without lymph node metastasis can rise to 82%. 3. In any case, the prognosis for stage IV cases is still poor, with a survival rate of only 53%. If your child is diagnosed with nephroblastoma, he or she should go to the hospital immediately for treatment. Early treatment under the guidance of a doctor can greatly improve your child’s chances of survival. Do not delay, as it may aggravate the disease and jeopardize the child’s life.